Abstract: ObjectiveTo evaluate efficacy of caspofungin combined with trimethoprimsulfamethoxazole (TMPSMZ) in treatment of AIDS complicated with pneumocystis pneumonia (PCP). MethodsThe study enrolled 102 AIDS patients complicated with PCP who were treated with caspofungin combined with TMPSMZ. In the meantime， 102 patients treated with TMPSMZ alone and matched with age， gender and admission condition were selected as control group. The therapeutic efficacy was  analyzed between  two groups. ResultsAfter antiPCP treatment， changes of PaO2， plasma β(1，3)Dglucan and serum LDH in combination treatment group were (13.4±7.9) mmHg（1 mmHg=0.133 kPa）， (123.9±84.6) ng/L and (104.5±58.9) U/L， respectively， and those in control group were (10.2±6.7) mmHg， (98.6±83.7) ng/L and (87.3±63.4) U/L， respectively. There were significant differences between two groups (P=0.002，0.033 and 0.046， respectively). There were no significant difference  in WBC count， liver and kidney function between two groups (P>0.05). Effective rate was  significantly  higher in the combined group than that in control group (93.1% vs  82.4%，P=0.034). ConclusionCaspofungin combined with TMPSMZ is more effective than TMPSMZ alone in AIDS patients complicated with PCP， which is worthy of further clinical validation.

Key words: acquired immunodeficiency syndrome, pneumonia, sulfamethoxazole, caspofungin